Table 1 Baseline characteristics and symptom burden of participants with advanced cancer, who filled out the cross-sectional symptom assessment survey.

From: The feasibility of a Bayesian network model to assess the probability of simultaneous symptoms in patients with advanced cancer

Characteristics

Participants n = 532

n (%)

Age category

30–45 years

15 (2.8)

46–67 years

208 (39.1)

68–80 years

222 (41.7)

 ≥ 81 years

84 (15.8)

Unknown

3 (0.6)

Gender

Male

277 (52.1)

Female

252 (47.4)

Unknown

3 (0.6)

Primary cancer sitea

Breast

69 (13.0)

Melanoma

16 (3.0)

Lymphatic system/ leukemia

17 (3.2)

Bladder/urinary tract

23 (4.3)

Colon

81 (15.2)

Lung

101 (19.0)

Prostate

56 (10.5)

Kidney

14 (2.6)

Endometrium

6 (1.1)

Ovaries

16 (3.0)

Pancreas

34 (6.4)

Head/neck

23 (4.3)

Esophagus

15 (2.8)

Liver

10 (1.9)

Brain

13 (2.4)

Neuroendocrine tumours

10 (1.9)

Otherb

71 (13.3)

Metastases

Yes

373 (70.1)

Disease modifying treatment during last 3 months

Systemic therapyc

263 (49.4)

Radiotherapy

132 (24.8)

Surgery

44 (8.3)

No

192 (36.0)

Patient-reported functional statusd

0

61 (11.5)

1

178 (33.5)

2

95 (17.9)

3

145 (27.3)

4

45 (8.5)

Place of residence

At home

275 (51.7)

Hospital

75 (14.1)

Hospice

158 (29.7)

Nursing home

10 (1.9)

Othere

4 (0.8)

Symptom score ≥ 4

Pain

195 (36.6)

Sleeping problems

209 (39.3)

Dry mouth

241 (45.3)

Dysphagia

111 (20.9)

Lack of appetite

274 (51.5)

Constipation

265 (49.8)

Nausea

64 (12.0)

Shortness of breath

99 (18.6)

Fatigue

344 (64.7)

Anxiety

131 (24.6)

Depressed mood

161 (30.3)

  1. aCancer site exceeds 100% because patients had more than one primary cancer site.
  2. bOther primary cancer sites: Bonemarrow, M. Kahler, multiple myeloma, bone, gallbladder, cholangiocarcinoma, small intestine, anal cancer, stomach cancer, basal skin carcinoma, squamous cell carcinoma of the skin, leiomyosarcoma, sarcoma, GIST, cervical cancer, vaginal cancer, mesothelioma.
  3. cChemotherapy and/or hormone therapy and/or immunotherapy and/or other (intravenous immunoglobulin therapy, angiogenesis inhibitors, BRAF targeted therapy, unspecified targeted therapy).
  4. dPatient-reported functional status22: 0 = normal with no limitations; 1 = not my normal self, but able to be up and about with fairly normal activities; 2 = not feeling up to most things, but in bed or chair less than half of the day; 3 = able to do little activity and spend most of the day in bed or chair; 4 = pretty much bedridden, rarely out of bed.
  5. eLiving facility for mentally disabled people, rehabilitation center, care home, care hotel.